These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35154085)

  • 21. Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs.
    Ovejero-Benito MC; Muñoz-Aceituno E; Sabador D; Almoguera B; Prieto-Pérez R; Hakonarson H; Coto-Segura P; Carretero G; Reolid A; Llamas-Velasco M; Abad-Santos F; Daudén E
    Exp Dermatol; 2020 Dec; 29(12):1225-1232. PubMed ID: 33058233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
    Chiu HY; Chu TW; Cheng YP; Tsai TF
    PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital.
    Elberdín L; Fernández-Torres R; Paradela S; Blanco E; Outeda M; Martín I; Fonseca E
    J Dermatolog Treat; 2020 Nov; 31(7):698-701. PubMed ID: 30961404
    [No Abstract]   [Full Text] [Related]  

  • 24. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
    van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and effectiveness of ustekinumab for treatment of moderate to severe psoriasis: a prospective study in a clinical setting.
    Molina-Leyva A; Husein-Elahmed H; Naranjo-Sintes R; Ruiz-Carrascosa JC
    J Drugs Dermatol; 2014 Aug; 13(8):971-4. PubMed ID: 25116977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
    Al-Salama ZT; Scott LJ
    Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom.
    Warren RB; Halliday A; Graham CN; Gilloteau I; Miles L; McBride D
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2178-2184. PubMed ID: 29846965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction between Smoking and HLA-C*06:02 on the Response to Ustekinumab in Psoriasis.
    Svedbom A; Nikamo P; Ståhle M
    J Invest Dermatol; 2020 Aug; 140(8):1653-1656.e1. PubMed ID: 32014510
    [No Abstract]   [Full Text] [Related]  

  • 31. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.
    Talamonti M; Galluzzo M; Chimenti S; Costanzo A
    J Am Acad Dermatol; 2016 Feb; 74(2):374-5. PubMed ID: 26775778
    [No Abstract]   [Full Text] [Related]  

  • 32. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and
    Kim SJ; Park MY; Pak K; Han J; Kim GW; Kim HS; Ko HC; Kim MB; Kim BS
    J Dermatolog Treat; 2018 Dec; 29(8):761-768. PubMed ID: 29658378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
    Galluzzo M; Boca AN; Botti E; Potenza C; Malara G; Malagoli P; Vesa S; Chimenti S; Buzoianu AD; Talamonti M; Costanzo A
    Dermatology; 2016; 232(2):230-6. PubMed ID: 26678060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy.
    Galluzzo M; D'Adamio S; Campione E; Bianchi L; Talamonti M
    Mol Diagn Ther; 2018 Dec; 22(6):717-721. PubMed ID: 30076588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks.
    Toro-Montecinos M; Ballescá F; Ferrandiz C; Teniente-Serra A; Martinez-Caceres E; Carrascosa JM
    J Dermatolog Treat; 2019 Feb; 30(1):35-39. PubMed ID: 29683393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.
    Del Alcázar E; Ferran M; López-Ferrer A; Notario J; Vidal D; Riera J; Aparicio G; Gallardo F; Vilarrasa E; Alsina M; Puig L; Ferrándiz C; Carrascosa JM
    J Dermatolog Treat; 2020 May; 31(3):222-226. PubMed ID: 30883242
    [No Abstract]   [Full Text] [Related]  

  • 37. Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis.
    Augustin M; Blome C; Paul C; Puig L; Luger T; Lambert J; Chimenti S; Girolomoni G; Kragballe K; Naessens D; Bergmans P; Smirnov P; Barker J; Reich K
    J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):294-303. PubMed ID: 27515070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ustekinumab for the treatment of moderate to severe psoriasis.
    Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.